FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

5-Amino-1MQ

5-Amino-1-Methylquinolinium

Weight Loss & Metabolic

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.

작용 메커니즘

Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 50-150mg orally once daily. Often taken with food.

연구 노트

Clinical Research Status

5-Amino-1MQ is in preclinical development with published in vitro and animal model data but has not yet entered formal human clinical trials. Research is primarily based on studies from the University of Texas Health Science Center demonstrating its effects on adipocyte differentiation and metabolic pathways. The compound is available through research chemical suppliers and compounding pharmacies, though it lacks regulatory approval for any therapeutic indication.

Key Published Findings

Studies in diet-induced obesity mouse models showed that 5-Amino-1MQ treatment reduced body weight by approximately 7% over 11 days without affecting food intake or causing lean mass loss. In vitro research demonstrated that NNMT inhibition with 5-Amino-1MQ reduced lipid accumulation in differentiating adipocytes and increased intracellular NAD+ levels by 2-fold. The compound has been shown to shrink existing fat cells, prevent new fat cell maturation, and increase the activity of sirtuin-dependent metabolic pathways through NAD+ elevation.

Safety Profile

Preclinical toxicity data suggests 5-Amino-1MQ is well-tolerated in animal models at effective doses without significant organ toxicity or behavioral changes. As a relatively new research compound without human trial data, the long-term safety profile in humans remains uncharacterized. Users in the research community have self-reported generally mild side effects at doses of 50-150mg daily, though systematic adverse event data is absent.

Drug Interactions & Contraindications

Theoretical interactions exist with other compounds that affect methyl donor metabolism, including SAM-e supplements and medications metabolized by methyltransferase enzymes. Given its mechanism of increasing intracellular NAD+, concurrent use with NAD+ precursors (NMN, NR) may produce additive effects that are not yet characterized for safety. Individuals with hormone-sensitive conditions should exercise caution, as NNMT plays roles in estrogen and catecholamine metabolism.

Comparison to Related Compounds

Unlike traditional fat loss compounds that work through appetite suppression or thermogenesis (DNP, clenbuterol), 5-Amino-1MQ targets the metabolic programming of fat cells themselves through epigenetic regulation. Other NNMT inhibitors exist in research (methylquinolinium analogs), but 5-Amino-1MQ is the most characterized and commercially available for research purposes. Its mechanism of simultaneously increasing NAD+ and SAM makes it mechanistically distinct from direct NAD+ precursors like NMN, which do not address NNMT-mediated metabolic dysregulation.

Community Observations

Users typically report subtle but measurable changes in body composition over 4-8 weeks at oral doses of 50-150mg daily, with fat loss concentrated in visceral and stubborn subcutaneous depots. The compound is frequently stacked with other metabolic agents and exercise programs, making isolated effects difficult to assess in anecdotal reports. The research community notes that 5-Amino-1MQ appears to work best as a recomposition agent rather than a dramatic weight loss compound, and effects seem more pronounced in individuals with higher baseline body fat percentages.

반감기

~2-3 hours (oral)

재조성

N/A (oral capsule form)

보관

건조한 상태

Room temperature. Protect from moisture and light.

재조성된 상태

N/A (oral form)

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

5-Amino-1-Methylquinolinium

자주 묻는 질문

5-Amino-1MQ란 무엇인가요?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.

5-Amino-1MQ는 어떻게 작용하나요?

Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.

5-Amino-1MQ의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

5-Amino-1MQ의 반감기는 얼마인가요?

~2-3 hours (oral)

5-Amino-1MQ의 다른 이름은 무엇인가요?

5-Amino-1-Methylquinolinium

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기